In the BioHarmony Drug Report Database

"Preview" Icon

Infigratinib

Truseltiq (infigratinib) is a small molecule pharmaceutical. Infigratinib was first approved as Truseltiq on 2021-05-28. It is used to treat cholangiocarcinoma in the USA. The pharmaceutical is active against fibroblast growth factor receptor 1, fibroblast growth factor receptor 2, and fibroblast growth factor receptor 3. In addition, it is known to target vascular endothelial growth factor receptor 2 and fibroblast growth factor receptor 4. Truseltiq’s patent is valid until 2034-12-11 (FDA).

 

Trade Name

 

Truseltiq
 

Common Name

 

infigratinib
 

ChEMBL ID

 

CHEMBL1852688
 

Indication

 

cholangiocarcinoma
 

Drug Class

 

Tyrosine kinase inhibitors

Image (chem structure or protein)

Infigratinib structure rendering